Diabetes and the gastrointestinal tract
Gastrointestinal (GI) complications of diabetes mellitus are common and substantially decrease health-related quality of life. Diabetes can affect every part of the GI tract, from the oesophagus to the rectum, and causes various symptoms, including reflux, heartburn, nausea, vomiting, abdominal pain, diarrhoea and constipation. Diabetes-induced GI complications are collectively referred to as diabetic gastroenteropathy. Over recent years, investigation of the underlying pathogenesis of diabetes-induced GI complications has provided objective evidence of abnormalities in the enteric nervous system, essential for normal moti...
Source: Medicine - April 11, 2024 Category: Internal Medicine Authors: Anne-Marie Wegeberg, Christina Brock Tags: New advances Source Type: research
Low-dose colchicine for atherosclerosis: long-term safety
Eur Heart J. 2024 Apr 10:ehae208. doi: 10.1093/eurheartj/ehae208. Online ahead of print.ABSTRACTLow-dose colchicine (0.5 mg daily) is now FDA-approved for secondary prevention in patients with coronary disease and will be increasingly prescribed in clinical practice. In this State-of-the-Art Review, data were collated from contemporary systemic reviews of case reports, drug registries, and placebo-controlled trials that assessed specific issues of safety related to the continuous use of colchicine in a range of clinical settings to inform physicians, pharmacists, and patients of the absolute risks of continuous use of low-...
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Stefan Mark Nidorf Eldad Ben-Chetrit Paul M Ridker Source Type: research
Low-dose colchicine for atherosclerosis: long-term safety
Eur Heart J. 2024 Apr 10:ehae208. doi: 10.1093/eurheartj/ehae208. Online ahead of print.ABSTRACTLow-dose colchicine (0.5 mg daily) is now FDA-approved for secondary prevention in patients with coronary disease and will be increasingly prescribed in clinical practice. In this State-of-the-Art Review, data were collated from contemporary systemic reviews of case reports, drug registries, and placebo-controlled trials that assessed specific issues of safety related to the continuous use of colchicine in a range of clinical settings to inform physicians, pharmacists, and patients of the absolute risks of continuous use of low-...
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Stefan Mark Nidorf Eldad Ben-Chetrit Paul M Ridker Source Type: research
Low ‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
In conclusion, preliminary results indicated that low-dose venetoclax combined with azacitidine is effective and safe for the treatment of older and frail patients with newly diagnosed AML, providing a new treatment option for these patients.PMID:38586209 | PMC:PMC10996028 | DOI:10.3892/ol.2024.14362 (Source: Oncology Letters)
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Chunmeng Rong Fang Yang Yalu Chen Ming Wang Cheng Ai Yuqing Luo Panpan Gao Yiqin Weng Xiaguang Huang Meier Gu Weiping Huang Yongming Xia Source Type: research
Preoperative nutrition therapy in people undergoing gastrointestinal surgery
CONCLUSIONS: We were unable to determine if parenteral nutrition, enteral nutrition, immune-enhancing nutrition or standard oral nutrition supplements have any effect on the clinical outcomes due to very low-certainty evidence. There is some evidence that standard oral nutrition supplements may have no effect on complications. Sensitivity analysis showed standard oral nutrition supplements probably reduced infections in weight-losing or malnourished participants. Further high-quality multicentre research considering the ERAS programme is required and further research in low- and middle-income countries is needed.PMID:38588...
Source: Cochrane Database of Systematic Reviews - April 8, 2024 Category: General Medicine Authors: Anne Marie Sowerbutts Sorrel Burden Jana Sremanakova Chloe French Stephen R Knight Ewen M Harrison Source Type: research
Chronic underlying gastrointestinal amyloidosis was revealed by cardiac echography: a case report from Syria
CONCLUSION: This case reminds us to consider amyloidosis as a possible underlying cause for unexplained gastrointestinal symptoms such as diarrhoea, especially in bad economic situations where the diagnosis of rare diseases may be delayed.PMID:38576978 | PMC:PMC10990300 | DOI:10.1097/MS9.0000000000001901 (Source: Annals of Medicine)
Source: Annals of Medicine - April 5, 2024 Category: Internal Medicine Authors: Ali Asaad Yahia Ranjous Zein Aldeen Hassan Nazir Alahmad Lama Ghanimeh Ayman Ali Source Type: research
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study
CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177 (Source: Cell Research)
Source: Cell Research - April 5, 2024 Category: Cytology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study
CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research
Chronic underlying gastrointestinal amyloidosis was revealed by cardiac echography: a case report from Syria
CONCLUSION: This case reminds us to consider amyloidosis as a possible underlying cause for unexplained gastrointestinal symptoms such as diarrhoea, especially in bad economic situations where the diagnosis of rare diseases may be delayed.PMID:38576978 | PMC:PMC10990300 | DOI:10.1097/MS9.0000000000001901 (Source: Annals of Medicine)
Source: Annals of Medicine - April 5, 2024 Category: Internal Medicine Authors: Ali Asaad Yahia Ranjous Zein Aldeen Hassan Nazir Alahmad Lama Ghanimeh Ayman Ali Source Type: research
Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report
We report the first case of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis as a systemic immune-related adverse event in a 64-year-old man receiving pembrolizumab to treat advanced lung cancer. The patient experienced hypothyroidism, myalgia, skin involvement, dyspnoea and diarrhoea. Laboratory tests revealed raised inflammatory markers, hypercreatinekinasemia and anti-MDA5 autoantibodies. Electroneuromyography and pathognomonic signs on physical examination confirmed the diagnosis of pauci-myopathic dermatomyositis. Pembrolizumab was discontinued and immunosuppressive therapy led to rapid ...
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Antonino Marcello Pilia Lorenzo Salvati Alessia Guidolin Francesca Mazzoni Lorenzo Antonuzzo Paola Parronchi Francesco Liotta Source Type: research
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study
CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177 (Source: Cell Research)
Source: Cell Research - April 5, 2024 Category: Cytology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study
CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research
Chronic underlying gastrointestinal amyloidosis was revealed by cardiac echography: a case report from Syria
CONCLUSION: This case reminds us to consider amyloidosis as a possible underlying cause for unexplained gastrointestinal symptoms such as diarrhoea, especially in bad economic situations where the diagnosis of rare diseases may be delayed.PMID:38576978 | PMC:PMC10990300 | DOI:10.1097/MS9.0000000000001901 (Source: Annals of Medicine)
Source: Annals of Medicine - April 5, 2024 Category: Internal Medicine Authors: Ali Asaad Yahia Ranjous Zein Aldeen Hassan Nazir Alahmad Lama Ghanimeh Ayman Ali Source Type: research
Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report
We report the first case of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis as a systemic immune-related adverse event in a 64-year-old man receiving pembrolizumab to treat advanced lung cancer. The patient experienced hypothyroidism, myalgia, skin involvement, dyspnoea and diarrhoea. Laboratory tests revealed raised inflammatory markers, hypercreatinekinasemia and anti-MDA5 autoantibodies. Electroneuromyography and pathognomonic signs on physical examination confirmed the diagnosis of pauci-myopathic dermatomyositis. Pembrolizumab was discontinued and immunosuppressive therapy led to rapid ...
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Antonino Marcello Pilia Lorenzo Salvati Alessia Guidolin Francesca Mazzoni Lorenzo Antonuzzo Paola Parronchi Francesco Liotta Source Type: research
